Overview

Paradromics positions Connexus as the world’s highest-data-rate BCI, designed to capture neural signals at high resolution for complex motor and communication tasks. Founded in 2015 and headquartered in Austin, the company raised a $33 million Series A led by Prime Movers Lab in 2023 and earlier won about $18 million in DARPA research funding through the Neural Engineering System Design programme.

Technical Specifications

The Connexus cortical module carries 421 platinum-iridium microelectrodes, each thinner than a human hair, recording from individual neurons. This high channel density is engineered to capture distributed neural populations across motor and language areas simultaneously, enabling decoding of complex speech intentions from neural signals.

Clinical Milestones

Paradromics achieved first-in-human recording in June 2025 during an epilepsy surgery, demonstrating safety of the high-channel implant in a human patient. The company subsequently received FDA approval for its Connect-One clinical study in November 2025, establishing a pathway to recruit paralyzed patients with speech impairment. The first Connexus implant took place at University of Michigan Health on 17 June 2026. On 26 August 2026 the FDA approved connecting the system to participants’ own computers, tablets and phones, and on 14 September 2026 Paradromics reported the first participant speaking her own words in real time. William J. Marks Jr. joined as Chief Clinical Officer on 7 July 2026.

Market Positioning

By prioritising speech restoration over gross motor control, Paradromics targets a distinct patient population and addresses a high-value unmet need.